rare diseases

Graphic image of a red thumbs down against a blue background
Biotech

FDA rejects Biohaven approval request, triggering cost cutting

Biohaven responded to the rejection of its neurological disorder therapy by reprioritizing its pipeline to shrink its annual R&D spend by 60%.
Nick Paul Taylor Nov 5, 2025 4:02am
On target clinical trial success bullseye score

Sanofi's $1.7B bet beats CSL's Zemaira in phase 2 face-off

Oct 22, 2025 10:35am
purple lightning tornado

Electra shines with $183M fundraise for rare disease trial

Oct 22, 2025 8:26am
graphic art of a right hand signing something

Hansoh, Chugai ink separate and lucrative licensing agreements

Oct 17, 2025 11:04am
An artists impression of DNA The DNA appears to be made up of glowing orbs and appears on a blue background

James Wilson's GEMMABio launches new gene therapy biotech

Oct 7, 2025 10:00am
Tiny green sprout growing from soil

Chiesi fertilizes Arbor's gene therapy with $2B biobucks deal

Oct 6, 2025 7:00am